

HISTOLOGICAL AND NEUROENDOCRINE MECHANISMS OF PREMENSTRUAL SYNDROME: A CLINICAL AND MICROSCOPIC PERSPECTIVE

Abdumannopova Nigora Sobirjon qizi

*Student of the Faculty of Second Medical Treatment,
Tashkent Medical Academy. Phone: 99 478 68 07*

Scientific Advisor: Tursunmetov Ibodulla

*Department of Medical Biology and Histology,
Tashkent Medical Academy*

Abstract: Premenstrual syndrome (PMS) affects a majority of women during their reproductive years, with symptoms that extend beyond mood swings to include histologically rooted changes. This article explores the interplay between hormonal fluctuations and tissue-level responses in the brain and reproductive system. Using both personal observations and academic literature, the study identifies how estrogen, progesterone, and neurotransmitters like serotonin contribute to PMS. Through this dual analysis, we highlight the biological basis of symptoms often dismissed as minor. Diagrams and tables are included to aid in visualizing these complex mechanisms. This paper aims to provide both scientific insight and practical understanding of PMS.

Key words: Premenstrual syndrome (PMS), Hormonal fluctuations, Estrogen, Progesterone, Histological changes, Neuroendocrine mechanisms, Menstrual cycle, GABA receptors, Serotonin, Endometrial inflammation.

Introduction

Premenstrual syndrome (PMS) is a multifactorial condition that arises in the luteal phase of the menstrual cycle, usually 5–10 days before menstruation. Characterized by a range of physical, emotional, and cognitive symptoms, PMS is experienced by up to 85% of reproductive-aged women. Symptoms such as breast tenderness, nausea, irritability, anxiety, and sleep disturbances are often regarded as routine, but in reality, they are the result of complex neuroendocrine and histological interactions.

The fluctuations in estrogen and progesterone levels affect not only mood and behavior but also tissue-level changes in the endometrium, hypothalamus, and limbic system. Despite its prevalence, the biological basis of PMS remains poorly understood by the general public. This paper investigates the neuroendocrine feedback loops and histological changes that occur during PMS, providing an in-depth yet accessible explanation of a familiar phenomenon.

Methods

This study combines personal observation with scientific research. A small informal survey and individual interviews were conducted among 20 female medical students aged 18–24. Participants were asked to report symptoms experienced during the premenstrual phase. Commonly reported issues included mood instability, food cravings, bloating, fatigue, and increased sensitivity.


To complement the observational data, a literature review was performed using PubMed, ScienceDirect, and Google Scholar. Search terms included “PMS,” “histological changes in PMS,” “neuroendocrine mechanisms,” and “estrogen progesterone brain effect.” Articles published between 2013 and 2023 were selected to ensure recent data. Key focus areas included brain tissue response to hormone shifts, neurotransmitter involvement, and immune cell activity in uterine and CNS tissues.

Results

The informal survey revealed the most common PMS symptoms among participants as follows:

Figure 1: Prevalent PMS Symptoms

| Symptom | Reported by (%) |
|----------------------|-----------------|
| Mood swings | 85% |
| Breast tenderness | 75% |
| Nausea or bloating | 60% |
| Irritability/anxiety | 70% |
| Food cravings | 50% |
| Sleep disturbances | 55% |



Histologically, PMS is associated with the following key changes:

Neuroendocrine activity: Estrogen and progesterone modulate the release of neurotransmitters such as serotonin and GABA. Decreased serotonin levels in the midbrain correlate with increased mood lability.

Tissue response: Endometrial tissue undergoes changes due to progesterone withdrawal, resulting in increased prostaglandin production, which can lead to nausea and cramps.

Immune activation: Elevated cytokine levels and immune cell activity are observed in both the uterus and brain, contributing to fatigue and behavioral shifts.


Discussion

The connection between fluctuating sex hormones and observable symptoms in PMS lies in the tissue-level impact on the central nervous system and reproductive organs. Progesterone, which increases in the luteal phase and then drops sharply before menstruation, has an inhibitory effect on neuronal excitability. This decline can lead to irritability and emotional instability due to reduced GABA activity.

Moreover, serotonin production is closely tied to estrogen levels. When estrogen decreases, serotonin synthesis and receptor sensitivity are reduced, explaining the mood-related symptoms. Histological studies reveal altered glial cell activity and neurotransmitter receptor expression in the hypothalamus during this phase.

In the endometrial lining, progesterone withdrawal leads to increased prostaglandin secretion, which is associated with inflammation, pain, and gastrointestinal symptoms such as nausea and bloating. These mechanisms reflect how cyclical hormonal changes translate into physical discomfort and behavioral changes.

Despite being seen as a normal part of life, PMS involves significant histological and biochemical changes. Raising awareness of this biology helps validate the experiences of affected individuals and encourages a more supportive approach in clinical practice.



Conclusion

PMS is not merely a hormonal shift but a complex interplay of neuroendocrine signals and histological changes. Recognizing its biological roots enables a better understanding of the condition, promoting empathy and targeted treatment strategies. Further research and public education are essential to dispel misconceptions and provide effective care for those affected.

References

1. Rapkin, A.J., & Winer, S.A. (2009). Premenstrual syndrome and premenstrual dysphoric disorder: Quality of life and burden of illness. *Expert Review of Pharmacoeconomics & Outcomes Research*, 9(2), 157–170.
2. Halbreich, U. (2003). The etiology, biology, and evolving pathology of premenstrual syndromes. *Psychoneuroendocrinology*, 28, 55–99.
3. Yonkers, K.A. et al. (2008). The role of serotonin in premenstrual syndrome. *CNS Drugs*, 22(6), 477–492.
4. Smith, M.J., & Rubinow, D.R. (2018). Endocrine and immune regulation of mood during the menstrual cycle. *Journal of Neuroendocrinology*, 30(7).
5. Freeman, E.W. (2003). Premenstrual syndrome and premenstrual dysphoric disorder: Definitions and diagnosis. *Psychoneuroendocrinology*, 28, 25–37.